An unusual case of respiratory failure and dropped head syndrome as a complication of severe chronic graft-versus-host disease (GVHD)-related polymyositis is described. The patient required tracheostomy and mechanical ventilation but recovered following treatment with aggressive immunosuppression and intensive rehabilitation. The differential diagnoses of muscle weakness in the bone marrow transplant (BMT) patient and the dropped head syndrome are both discussed. To our knowledge, this is the first reported case of respiratory failure requiring mechanical ventilation occurring as a complication of GVHD-related polymyositis. Bone Marrow Transplantation (2000) 26, 1117-1120. Keywords: polymyositis; GVHD; respiratory failure; BMT; dropped head syndrome Respiratory failure in the setting of bone marrow transplantation (BMT) is usually acute in onset and occurs due to a number of well described but poorly understood clinical syndromes that occur in this patient population. The clinical syndromes include diffuse alveolar hemorrhage, 1 the idiopathic pneumonia syndrome, 2 septic shock, 3 pneumonia due to conventional and opportunistic organisms 4 or bronchiolitis obliterans.
Respiratory failure in the setting of bone marrow transplantation (BMT) is usually acute in onset and occurs due to a number of well described but poorly understood clinical syndromes that occur in this patient population. The clinical syndromes include diffuse alveolar hemorrhage, 1 the idiopathic pneumonia syndrome, 2 septic shock, 3 pneumonia due to conventional and opportunistic organisms 4 or bronchiolitis obliterans. 5 Chronic respiratory failure as a complication of muscle weakness in this patient population is not well described and appears to be very uncommon. Polymyositis is a recognized but unusual complication of chronic graft-versus-host disease (GVHD) due to BMT. 6 We report a patient who developed GVHD-related polymyositis that resulted in profound weakness of both the extensor muscles of the neck and muscles of respiration. The patient gradually developed respiratory failure and ultimately required a tracheostomy and mechanical ventilation. To our knowledge, GVHD as a cause of chronic respiratory failure has not been previously described. The differential diagnoses of respiratory muscle weakness in the BMT patient and the 'dropped head syndrome' are both discussed.
Case report
A 37-year-old female who had undergone a matched unrelated allogeneic BMT 2 years prior to admission presented with a several month history of progressive weakness of the muscles of both shoulders, neck and thighs. She had difficulty performing simple tasks such as combing her hair and brushing her teeth. In addition, she had diffuse myalgias and dysphagia for both liquids and solids. Ten years previously she had been diagnosed with acute myeloid leukemia (M2) (AML) that responded to chemotherapy. The disease relapsed 7 years later and she was treated with induction chemotherapy, two cycles of consolidation followed by a matched (6/6) unrelated allogeneic BMT from an ABO incompatible donor. She received a standard conditioning regimen comprising cyclophosphamide and total body irradiation. Routine pulmonary function tests performed prior to BMT were all normal. Her course following BMT was complicated by grade 1 acute and then extensive chronic GVHD, involving primarily the oral mucosa and skin. This was treated with corticosteroids (prednisone 10-20 mg per day) and cyclosporine. Her medications at the time of presentation included cyclosporine 50 mg daily, nifedipine extended release 30 mg daily, prednisone 20 mg daily and trimethoprim/sulfamethoxazole double strength three times a week for P. carinii prophylaxis.
Positive findings on physical examination included a Cushingoid appearance, focal areas of alopecia on the scalp and scleroderma-like changes with skin thickening, patchy areas of hyperpigmentation consistent with chronic GVHD over her neck, trunk and arms. Neurological examination revealed a mild, symmetric reduction in proximal motor strength (4/5) in all extremities. There was profound weakness of the neck extensor muscles (2/5) with an inability to keep her head elevated in a normal position. Neck flexion was normal. Laboratory testing revealed an elevated total creatinine phosphokinase (CPK) at 1445 U/l (normal range 20-165 U/l) and an elevated adolase of 24 U/l (normal range 1.7-4.9 U/l). Skin biopsy revealed an interface dermatitis and folliculitis consistent with evolving chronic GVHD. The following laboratory tests were normal: anti-nuclear antibody, rheumatoid factor, complement levels, anti-Jo antibody, anti-SSA, anti-SCL-70 and toxoplasma IgG titers. An electromyogram (EMG) performed on the muscles of the left arm and leg revealed small, hypercomplex and short duration motor unit action potentials and evidence of early recruitment in a patchy pattern. Fibrillation potentials and positive sharp waves were also found in the same muscles. Sensory and motor conduction was normal. These findings were consistent with a primary myopathy. Pulmonary function tests showed a moderate to severe restrictive pattern with a severe reduction in maximal inspiratory and expiratory pressures (Table 1) . Chest radiograph revealed a left lower lobe pneumonia. Arterial blood gas analysis revealed pH 7.33, pCO 2 52, pO 2 49 on oxygen (4 l/min) via nasal cannulae. The combination of restrictive physiology, reduced respiratory muscle strength and hypercarbia was considered diagnostic of respiratory muscle weakness. The widened A-a gradient was due to a left lower lobe pneumonia.
Based on these data a diagnosis of polymyositis secondary to chronic GVHD was made and she was started on intravenous methylprednisolone 80 mg daily in addition to antibiotics for the pneumonia. Despite an initial clinical improvement with resolution of the pneumonia, the muscle weakness slowly progressed with severe weakness in neck extension to the point she was unable to maintain her head in a normal position without the support of an external neck brace. A MRI of the neck with gadolinium was performed and revealed atrophy of the cervical and masticator muscles with intense enhancement seen in the tongue, platysma, paraspinus, sternocleidomastoid and trapezius muscles ( Figure  1 ). These findings were consistent with an active myositis. As a result of progressive weakness of her neck muscles and accessory muscles of respiration she gradually developed more difficulty in keeping her upper airway patent (despite a splint), in maintaining normal ventilation and in effectively clearing her secretions. She had numerous episodes of mucus plugging and atelectasis and ultimately underwent tracheostomy for both airway protection and mechanical ventilation. She was treated with an intensive regimen of immunosuppression for 6 months comprising monthly intravenous cyclophosphamide (1 g), methylprednisolone starting at 100 mg daily, mycophenylate mofetil 500 mg twice a day, monthly intravenous immunoglobulin (0.5 g per kg) and photopheresis for 2 days a month for the first 3 months. Over the 6 month period the dose of methylprednisolone was slowly tapered by 10 mg every 2 weeks provided the CPK continued to fall. The muscle weakness gradually improved on this regimen, the muscle enzymes normalized, the chronic GVHD regressed and she was successfully weaned from mechanical ventilation and eventually decannulated. Unfortunately, 1 year after her recovery she developed bacterial sepsis while on vacation and died.
Discussion
This patient with chronic GVHD experienced a myopathic syndrome with clinical, laboratory and radiological features of polymyositis. We believe this is the first reported case of a patient developing respiratory failure requiring mechanical ventilation as a complication of GVHD-related polymyositis. Polymyositis is a rare complication of chronic GVHD occurring in approximately 3% of the BMT population. 6, 7 The mean time from allogeneic BMT to onset of myositis ranges from 100 days to 54 months. 6, 8 As demonstrated in the case we describe, patients with GVHD-related polymyositis usually have other manifestations of acute or chronic GVHD. Polymyositis has been reported as the sole manifestation of chronic GVHD. 9 Presenting symptoms of GVHD-related polymyositis include moderate to severe proximal muscle weakness, myalgias and arthralgias. 6 Rarely, patients may present with muscle pain in the absence of any demonstrable weakness. 6 Supporting laboratory evidence includes an elevated total CPK (up to 40 times normal) and an elevated adolase. An elevated antinuclear antibody or rheumatoid factor level has been reported in GVHD-related polymyositis, 6 making it difficult to distinguish serologically between this disease and the polymyositis seen with connective tissue diseases.
Characteristic findings on muscle biopsy include multiple foci of muscle cell necrosis, interstitial fibrosis and infiltration with lymphocytes. 7 The majority of the infiltrating lymphocytes are T cells with a CD4/CD8 ratio of Ͻ1. The CD8-positive cells lack the T cell suppressor-associated antigen, Leu-15, indicating that they belong to the cytotoxic subclass. Other cell types that have been noted on biopsy included polyclonal B cells, lymphocytes expressing CD16 and CD57 (natural killer cells) and monocytic-histiocytic cells expressing CD68. 7 To our knowledge, analysis of restriction fragment length polymorphisms has not been performed on the infiltrating lymphocytes in GVHD-related polymyositis and therefore it is not possible to determine if the cells originate from donor or recipient. In polymyositis, the EMG shows a characteristic increase in small short polyphasic action potentials, the presence of which help exclude a steroid myopathy. 7 GVHD-related polymyositis usually responds to corticosteroids but may relapse as the corticosteroids are tapered. 8 In the case we report additional immunosuppressive therapy was required to manage the severe GVHD-related polymyositis. Patients usually require treatment for 5-30 months and the overall prognosis appears to depend more on the activity of the chronic GVHD rather than the severity of the polymyositis. 8 Although a muscle biopsy was not obtained, due to concerns about wound healing in the setting of extensive skin GVHD and steroid use, we believe that there is sufficient evidence to support a diagnosis of GVHD-related polymyositis in this case. The clinical features of polymyositis with elevated muscle enzymes, along with evidence of inflammation on MRI, all occurred in the setting of biopsy proven chronic GVHD. The patient's skin rash had the typical features of GVHD rather than dermatomyositis. The most compelling evidence supporting a diagnosis of GVHD-related polymyositis is the resolution of the polyBone Marrow Transplantation myositis at the same time as the chronic GVHD regressed with immunosuppressive therapy.
Possible causes of skeletal muscle weakness in the BMT patient include corticosteroid-induced myopathy, disuse atrophy, poor nutritional status, electrolyte disorders, druginduced muscle weakness and myasthenia gravis. Eleven cases of myasthenia gravis secondary to chronic GVHD have been reported in the literature. 10 It is clinically indistinguishable from classic myasthenia gravis and presents with ocular weakness, normal muscle enzymes and an abnormal response to repetitive nerve stimulation. These features serve to distinguish it from polymyositis. 10 In the BMT patient the disordered immune regulation of chronic GVHD disease is thought to trigger the development of, or release the inhibition of anti-acetylcholine receptor antibody B cell clones. 8 As with classic myasthenia gravis, patients with GVHD-related myasthenia gravis usually respond favorably to cholinesterase inhibitors and immunosuppressants. Recently, both myasthenia gravis and polymyositis have been reported to occur in the same patient. 11 An additional prominent feature of this patient's clinical presentation was weakness of the extensor muscles of the cervical spine resulting in her inability to maintain her head in the normal position. This clinical sign is known as the 'dropped head syndrome'. The syndrome has been described both as an isolated clinical entity and also as a manifestation of a generalized neuromuscular disorder. The differential diagnosis of the 'dropped head syndrome' includes myasthenia gravis, amyotrophic lateral sclerosis, motor neuron disease, polymyositis/dermatomyositis, nemaline myopathy 13 and isolated neck extensor myopathy. 12 Respiratory muscle weakness causing respiratory failure and requiring mechanical ventilation has not been previously reported in the BMT population. In the case described, the presence of both respiratory muscle weakness combined with impairment of control of the upper airway due to the 'dropped head syndrome' eventually precipitated respiratory failure. Conditions that may cause both the 'dropped head syndrome' and respiratory muscle weakness are listed in Table 2 .
In summary, this case demonstrates that respiratory failure and the dropped head syndrome may occur as severe manifestations of GVHD-related polymyositis. As the number of patients undergoing BMT increases and survival improves, clinicians should be aware that chronic respiratory failure due to skeletal muscle weakness can occur in patients with GVHD-related polymyositis. Table 2 Conditions that may cause weakness of both neck extensors and respiratory muscles Amyotrophic lateral sclerosis Myasthenia gravis Polymyositis/dermatomyositis Acid maltase deficiency Fascioscapulohumeral muscular dystrophy Myotonic dystrophy Nemaline myopathy Graft-versus-host disease
